- Market Capitalization, $K 911,035
- Shares Outstanding, K 46,648
- Annual Sales, $ 524,000 K
- Annual Income, $ 329,590 K
- 60-Month Beta 1.01
- Price/Sales 1.70
- Price/Cash Flow 2.56
- Price/Book 1.79
|Period||Period Low||Period High||Performance|
| || |
-3.24 (-14.23%)since 07/08/22
| || |
+5.62 (+40.40%)since 05/10/22
| || |
-10.09 (-34.06%)since 08/10/21
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael...
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
It just reported a packet of promising safety data for its flagship pipeline program.
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing...
|GX Genomics & Biotechnology ETF|
|S&P Smallcap 600 Pure Growth Invesco ETF|
|S&P Smallcap Health Care Invesco ETF|
|Bioshares Biotech Clinical Trial|
|Alps Medical Breakthroughs ETF|
|3rd Resistance Point||20.81|
|2nd Resistance Point||20.26|
|1st Resistance Point||19.90|
|1st Support Level||18.98|
|2nd Support Level||18.43|
|3rd Support Level||18.07|